Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 8/20 | 0.75 |
| ▸ | MMP2 | P08253 | 8/20 | 0.75 |
| ▸ | MMP9 | P14780 | 8/20 | 0.75 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.69 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.69 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.69 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851492 | 1.00 | MMP1 (0.75) | MMP1MMP2MMP9TRPA1TRPM2 | |
| SCHEMBL30538697 | 1.00 | MMP1 (0.75) | MMP1MMP2MMP9TRPA1TRPM2 | |
| SCHEMBL30335821 | 1.00 | MMP1 (0.75) | MMP1MMP2MMP9TRPA1TRPM2 | |
| SCHEMBL13854017 | 0.92 | TRPA1 (0.69) | MMP1MMP2MMP9TRPA1TRPM2 | |
| SCHEMBL10737761 | 0.91 | MMP1 (0.62) | MMP1MMP2MMP9TRPA1TRPM2 | |
| Piperidine SCHEMBL10896664 | 0.91 | MMP1 (0.62) | MMP1MMP2MMP9TRPA1TRPM2 | |
| Piperidine SCHEMBL10896663 | 0.91 | MMP1 (0.62) | MMP1MMP2MMP9TRPA1TRPM2 | |
| SCHEMBL12723664 | 0.88 | TRPA1 (0.65) | MMP1MMP2MMP9TRPA1TRPM2 | |
| SCHEMBL13556323 | 0.88 | TRPA1 (0.69) | MMP1MMP2MMP9TRPA1TRPM2 | |
| SCHEMBL9973849 | 0.88 | MMP1 (0.63) | MMP1MMP2MMP9TRPA1TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0074725-B1 | A METHOD FOR THE PRODUCTION OF NUCLEAR SUBSTITUTED CINNAMOYLANTHRANILIC ACID DERIVATIVES AND INTERMEDIATES THEREOF | Kissei Pharmaceutical Co. Ltd. (JP) | 1985-12-27 | — | — | EP | claimed |
| EP-0074725-A1 | A method for the production of nuclear substituted cinnamoylanthranilic acid derivatives and intermediates thereof | Kissei Pharmaceutical Co. Ltd. (JP) | 1983-03-23 | — | — | EP | claimed |
| CN-115894283-A | Tranilast derivative and preparation method and application thereof | 南京迈诺威医药科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-10280441-B2 | Host cells and methods for producing cinnamoyl anthranilate and analogs thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-07 | — | — | US | disclosed |
| EP-2799427-B1 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-12-04 | — | — | US | disclosed |
| EP-2799427-A1 | Therapeutic compounds | Fibrotech Therapeutics PTY LTD (AU) | 2014-11-05 | — | — | EP | disclosed |
| US-8765812-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-07-01 | — | — | US | disclosed |
| EP-2035369-B1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-06-25 | — | — | EP | disclosed |
| CN-101600683-B | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD AU | 2013-06-12 | — | — | CN | disclosed |
| US-20130078683-A1 | Host Cells and Methods for Producing Cinnamoyl Anthranilate and Analogs Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-28 | — | — | US | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| EP-2035369-A1 | THERAPEUTIC COMPOUNDS | Fibrotech Therapeutics PTY LTD (AU) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008003141-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | NFATC1, AADAC, NAT1 | MMP1 23/4885MMP2 97/4885MMP9 127/4885 |
| US-20100130497-A1 | Therapeutic Compounds | NFATC1, NAT1, AADAC | MMP1 19/4885MMP2 88/4885MMP9 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.